Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

2.

The role of the affective temperament in the treatment adherence in psychiatry.

Bahrini L, Damak R, Cheour M.

Pan Afr Med J. 2016 Sep 2;25:2. doi: 10.11604/pamj.2016.25.2.8400. eCollection 2016.

3.

Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.

Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, Barnett JH, Jones PB, Isohanni M, Remes AM, Koponen H, Miettunen J, Jääskeläinen E.

Psychiatry Res. 2017 Jan;247:130-138. doi: 10.1016/j.psychres.2016.10.085. Epub 2016 Nov 12.

4.

Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder.

Sajatovic M, Levin JB, Sams J, Cassidy KA, Akagi K, Aebi ME, Ramirez LF, Safren SA, Tatsuoka C.

Bipolar Disord. 2015 Sep;17(6):653-61. doi: 10.1111/bdi.12326.

5.

Effect of a Multi-Dimensional and Inter-Sectoral Intervention on the Adherence of Psychiatric Patients.

Pauly A, Wolf C, Mayr A, Lenz B, Kornhuber J, Friedland K.

PLoS One. 2015 Oct 5;10(10):e0139302. doi: 10.1371/journal.pone.0139302. eCollection 2015.

6.

Antipsychotic drugs on maternal behavior in rats.

Li M.

Behav Pharmacol. 2015 Sep;26(6):616-26. doi: 10.1097/FBP.0000000000000168. Review.

7.

Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior.

Awad AG, Voruganti LL.

Ther Adv Psychopharmacol. 2015 Jun;5(3):172-8. doi: 10.1177/2045125315583820. Review.

8.

Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study.

Kutzelnigg A, Kopeinig M, Chen CK, Fábián A, Pujol-Luna MG, Shin YC, Treuer T, D'yachkova Y, Deix C, Kasper S, Doby D.

Int J Bipolar Disord. 2014 Oct 23;2(1):13. doi: 10.1186/s40345-014-0013-x. eCollection 2014 Dec.

9.

Comparing medication attitudes and reasons for medication nonadherence among three disparate groups of individuals with serious mental illness.

Levin JB, Seifi N, Cassidy KA, Tatsuoka C, Sams J, Akagi KK, Sajatovic M.

J Nerv Ment Dis. 2014 Nov;202(11):769-73. doi: 10.1097/NMD.0000000000000201.

10.

Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications.

Karthik MS, Warikoo N, Chakrabarti S, Grover S, Kulhara P.

Indian J Psychol Med. 2014 Jul;36(3):288-93. doi: 10.4103/0253-7176.135382.

11.

Patient choice as a driver of medication-switching in non-adherent individuals with bipolar disorder.

Sajatovic M, Tatsuoka C, Dines P, Bialko CS, Athey M, Williams T, Cassidy KA.

Patient Prefer Adherence. 2014 Apr 17;8:487-91. doi: 10.2147/PPA.S56790. eCollection 2014.

12.

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia.

Warikoo N, Chakrabarti S, Grover S.

Indian J Psychol Med. 2014 Jan;36(1):33-9. doi: 10.4103/0253-7176.127244.

13.

The psychoactive effects of psychiatric medication: the elephant in the room.

Moncrieff J, Cohen D, Porter S.

J Psychoactive Drugs. 2013 Nov-Dec;45(5):409-15.

14.

Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD.

J Clin Psychiatry. 2013 Dec;74(12):1249-55. doi: 10.4088/JCP.12m08331.

15.

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC.

BMC Psychiatry. 2013 Aug 22;13:214. doi: 10.1186/1471-244X-13-214.

16.

Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning.

Montes JM, Maurino J, de Dios C, Medina E.

Patient Prefer Adherence. 2013;7:89-94. doi: 10.2147/PPA.S39290. Epub 2013 Jan 18.

17.
18.

Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.

Medina E, Salvà J, Ampudia R, Maurino J, Larumbe J.

Patient Prefer Adherence. 2012;6:623-9. doi: 10.2147/PPA.S34345. Epub 2012 Aug 29.

19.

Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder.

Sajatovic M, Levin J, Tatsuoka C, Micula-Gondek W, Fuentes-Casiano E, Bialko CS, Cassidy KA.

Bipolar Disord. 2012 May;14(3):291-300. doi: 10.1111/j.1399-5618.2012.01010.x.

20.

Supplemental Content

Support Center